A group of researchers found that Drug combination therapy Can improve treatment Brain tumor patients In the past 50 years, its survival rate has hardly improved.
This work is already in National Cancer Research Center (CNIO), Here, scientists have conducted in-depth research on the deep resistance to the drug temozolomide, which is used as the main treatment method for the most aggressive brain tumor glioblastoma. This drug will gradually increase over time. Stop responding to the patient.
The researchers found The drug and another-double anhydrogalactose- CNIO today published the results of this study in the Journal of Molecular Cancer Therapeutics of the American Association for Cancer Research. CNIO reported that CNIO can help overcome these resistances and increase survival rates, which has been used in children with brain tumors. It was confirmed in the rat. .
Glioblastoma is More frequent and more aggressive brain tumorsCNIO emphasized that in the past 50 years, its survival rate has hardly improved, which highlights the urgent need to develop new treatment strategies.
The research team led by researcher Massimo Squaueble, head of the Cerf-Baleteros Foundation Brain Tumor Group of the National Cancer Research Center (CNIO), proposed a new treatment strategy based on The combination of these two drugs.
Squatrict explained to EFE that this is a “Very encouraging” preclinical work, However, this affects that unless the results are validated in a clinical setting, it is difficult to predict when the findings will be translated into beneficial treatments for patients with such tumors.
“Before getting the results, The actual impact on the patientThis combination must be tested in clinical trials to verify its safety and will not cause any related toxicity to them.
The scientist explained, “Temozolomide “has been approved for the treatment of glioblastoma, And the use of “Dianhydrogalactitol” is still being studied in clinical trials. So far, it has only been approved for the treatment of one type of leukemia and lung cancer in China.
CNIO recalled that at present, the main and almost only treatment for this type of brain tumor is Combining radiotherapy and chemotherapy with temozolomide“, after surgical removal of the tumor mass.
Like most chemotherapy used, Drugs cause damage to genetic material The apoptosis of tumor cells leads to their collapse and cell death. In almost half of patients, tumors develop resistance to the drug, and tumors continue to grow even during treatment.
“although The incidence of adult glioblastoma is not very highSqua recently pointed out that they are the most common brain tumors and there are no effective treatments or markers of response or resistance to treatment.
However, for patients with this type of tumor, what will happen if they stop responding to temozolomide?The researcher and his team have discovered this problem in previous studies, when they found The tumor managed to grow and avoid treatment.
Now, scientists have thoroughly studied the resistance to temozolomide and found Tumor cells accumulate mutations Enable them to avoid the effects of this drug.
Tumors are complex systems, They deployed multiple tools to deceive the human body CNIO has observed, and is able to grow and develop; and emphasizes that for many patients, one of the great revolutions and hopes is combination therapy, which targets several of these components that interfere with the tumor process.
Therefore, advances in the understanding of tumor molecular biology have made tumor development possible. The emergence of new therapies and their combinations Fight them in a targeted manner and avoid them from generating resistance.